For example, bevacizumab is a humanized monoclonal antibody targeting VEGF, has been approved by the US Food and Drug Administration (FDA) as a standard regimen for advanced NSCLC in the first-line setting. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.